BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)
  readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tivicay / Triumeq / Dovato / Juluca (comp
 onent) (Dolutegravir)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04892654-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT04892654)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Efficacy of Doravirine + Dolutegravir Dual Therap
 y in the Context of Antiretroviral Therapy Switch\nEstimated primary compl
 etion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dolutegravir#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04892654
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747507-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT06747507)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Ndovu RCT: Investing the Optimal Management of Do
 lutegravir Resistance\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06747507
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967753-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 4 readout est. (NCT06967753)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 4\, HIV.\nStudy: Switch to Dolutegravir Plus Lamivudine Dual-Thera
 py in Transgender Women Living With HIV on Virologically Suppressive Antir
 etroviral Therapy (TRANS-SWITCH)\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0696775
 3
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06281834-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 1 readout est. (NCT06281834)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 1\, HIV.\nStudy: Dolutegravir Pharmacokinetics During Weekly Rifap
 entine/Isoniazid for TB Prevention\nEstimated primary completion: 1 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dolutegravir
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062
 81834
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06805656-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 2 readout est. (NCT06805656)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 2\, HIV.\nStudy: Multi Interventional Approaches to Mitigate HIV R
 eservoirs for the Sustained HIV Remission Without Antiretrovirals\nEstimat
 ed primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dolutegravir#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06805656
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02656511-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 4 readout est. (NCT02656511)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 4\, HIV.\nStudy: Immediate Initiation of Antiretroviral Therapy Du
 ring "Hyperacute" HIV Infection\nEstimated primary completion: May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT02656511
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02140255-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 1/2 readout est. (NCT02140255)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 1/2\, HIV.\nStudy: Very Early Intensive Treatment of Infants Livin
 g With HIV to Achieve HIV Remission\nEstimated primary completion: 31 Janu
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dolutegravi
 r#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 140255
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05652478-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 2 readout est. (NCT05652478)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 2.\nStudy: Early Metabolic Effects of Antiretroviral Drugs in Heal
 thy volUnteers: a Phase 2 Randomized Study\nEstimated primary completion: 
 31 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dolu
 tegravir#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05652478
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497465-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT06497465)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Dolutegravir/Lamivudine Dual Therapy for ART-naï
 ve People With HIV and TB Receiving Rifampin-based TB Treatment\nEstimated
  primary completion: 31 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dolutegravir#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06497465
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555431-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 2 readout est. (NCT07555431)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 2.\nStudy: Dolutegravir Versus Dolutegravir in Combination With Te
 nofovir for the Treatment of HTLV-1 Infection\nEstimated primary completio
 n: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dolutegr
 avir#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07555431
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124559-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 1/2 readout est. (NCT07124559)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 1/2\, HIV.\nStudy: A Study of Daily Rifapentine Combined With Ison
 iazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of 
 Age With and Without HIV\nEstimated primary completion: 26 June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07124559
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616739-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 4 readout est. (NCT07616739)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 4\, HIV.\nStudy: Dolutegravir/Lamivudine in Treatment-Naïve Pregn
 ant Women\nEstimated primary completion: 15 October 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dolutegravir#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07616739
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792096-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT07792096)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: An Adaptive Platform Trial for Evaluation of Nove
 l Treatment Regimens in Children and Adolescents With HIV in Africa\nEstim
 ated primary completion: June 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dolutegravir#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07792096
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393659-1031@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20320914
DTEND;VALUE=DATE:20320915
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT07393659)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: A Continued Access Study for Participants Transit
 ioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Par
 ent Studies for HIV Treatment\nEstimated primary completion: 14 September 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073936
 59
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
